Profile data is unavailable for this security.
About the company
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
- Revenue in USD (TTM)0.00
- Net income in USD-51.23m
- Incorporated2011
- Employees16.00
- LocationSkye Bioscience Inc11250 EL CAMINO REAL, SUITE 100SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 410-0266
- Fax+1 (775) 782-2611
- Websitehttps://skyebioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 21.39m | 6.00 | -- | -- | -- | 61.04 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.85m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Exicure Inc | 0.00 | -9.23m | 22.63m | 8.00 | -- | 3.27 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 22.84m | 5.00 | -- | 1.24 | -- | 4.87 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 23.32m | 41.00 | -- | 1.74 | -- | 3.28 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 23.41m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.00m | -5.66m | 23.45m | 7.00 | -- | 0.7876 | -- | 1.56 | -2.12 | -2.12 | 5.77 | 5.52 | 0.5478 | -- | 26.19 | 2,142,857.00 | -20.68 | -35.39 | -22.63 | -39.01 | -- | -- | -37.76 | -375.66 | -- | -4.22 | 0.0011 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.59m | 16.00 | -- | 0.6945 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Vistagen Therapeutics Inc | 805.00k | -67.05m | 24.17m | 59.00 | -- | 0.4746 | -- | 30.02 | -1.90 | -1.90 | 0.0228 | 1.29 | 0.0102 | -- | -- | 14,375.00 | -85.21 | -55.19 | -99.91 | -59.56 | -- | -- | -8,328.70 | -5,842.62 | -- | -- | 0.0074 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.35m | 24.43m | 80.00 | -- | 25.98 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 24.72m | 46.00 | -- | -- | -- | 3.23 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 25.00m | 34.00 | -- | 3.08 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -22.76m | 25.16m | 14.00 | -- | 4.56 | -- | -- | -0.4722 | -0.4722 | 0.00 | 0.0472 | 0.00 | -- | -- | 0.00 | -207.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.79 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.30m | 64.00 | -- | 0.2296 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -45.26m | 25.43m | 60.00 | -- | 0.8172 | -- | -- | -14.47 | -14.47 | 0.00 | 9.79 | 0.00 | -- | -- | 0.00 | -48.69 | -49.32 | -61.70 | -53.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.54 | -- | -54.23 | -- |
Data as of Mar 04 2026. Currency figures normalised to Skye Bioscience Inc's reporting currency: US Dollar USD
12.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2025 | 1.45m | 4.53% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 774.00k | 2.41% |
| Sphera Funds Management Ltd.as of 31 Dec 2025 | 478.93k | 1.49% |
| Millennium Management LLCas of 31 Dec 2025 | 380.48k | 1.19% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 278.45k | 0.87% |
| Platinum Investment Management Ltd.as of 31 Dec 2025 | 233.10k | 0.73% |
| Geode Capital Management LLCas of 31 Dec 2025 | 210.15k | 0.66% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 104.23k | 0.33% |
| Schonfeld Strategic Advisors LLCas of 31 Dec 2025 | 93.41k | 0.29% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 75.33k | 0.24% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
